Kiora Pharmaceuticals
KPRX
14 hedge funds and large institutions have $5.57M invested in Kiora Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
33% less capital invested
Capital invested by funds: $8.31M → $5.57M (-$2.74M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$248K |
| 2 |
AG
Advisor Group
Phoenix,
Arizona
|
+$9.72K |
| 3 |
VF
Virtu Financial
New York
|
+$2.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$41.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$14.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.72K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$2.43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $5.43M | +$248K | +102 | +3% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $40K | – | – | – |
|
|
PAM
3
Panagora Asset Management
Boston,
Massachusetts
| $30K | -$14.6K | -6 | -25% |
|
|
VF
4
Virtu Financial
New York
| $23K | +$2.43K | +1 | +8% |
|
5
US Bancorp
Minneapolis,
Minnesota
| $12K | – | – | – |
|
|
GSWM
6
Golden State Wealth Management
Santa Ana,
California
| $8K | +$12.2K | +5 | New |
|
|
AG
7
Advisor Group
Phoenix,
Arizona
| $6K | +$9.72K | +4 | New |
|
|
WS
8
Wedbush Securities
Los Angeles,
California
| $5K | -$2.43K | -1 | -25% |
|
9
Northern Trust
Chicago,
Illinois
| $4K | – | – | – |
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
|
LTFS
11
Ladenburg Thalmann Financial Services
Miami,
Florida
| $3K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $2K | -$9.72K | -4 | -80% |
|
13
Morgan Stanley
New York
| $2K | – | – | – |
|
|
14
Acadian Asset Management
Boston,
Massachusetts
| $1K | -$41.3K | -17 | -94% |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$22K | -9 | Closed |
|
KPRX Hedge Fund Activity: Q1 2019 in Review
14 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2019, worth a combined $5.57M — down 33% from $8.31M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KPRX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, adding an estimated $248K. The largest seller was Acadian Asset Management, cutting an estimated $41.3K.
- 14 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2019, up from 13 in Q4 2018.
- Funds reported $5.57M of Kiora Pharmaceuticals stock for Q1 2019, down 33% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q1 2019 and 1 closed out, a net change of +1 holder.
- The largest Kiora Pharmaceuticals buyer in Q1 2019 was Armistice Capital, an estimated $248K added.
- The largest Kiora Pharmaceuticals seller in Q1 2019 was Acadian Asset Management, an estimated $41.3K sold.
Based on aggregated 13F filings for Q1 2019.